Transition zone ratio and prostate-specific antigen density: The index of response of benign prostatic hypertrophy to an alpha blocker

International Journal of Urology

Volumn 3, Issue 5, 1996, Pages 361-366

  Kurita, Yutaka ^a   Ushiyama, Tomomi ^a   Suzuki, Kazuo ^a   Fujita, Kimio ^a   Kawabe, Kazuki ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Benign prostatic hyperplasia; Prostate specific antigen density; Transition zone; Ultrasonography; blocker

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; SYMPTOM; TRANSRECTAL ULTRASONOGRAPHY; UROFLOWMETRY;

EID: 0029778212     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00554.x     Document Type: Article

References (23)

1. Caine M, Plau A, Perlberg S. A use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255-263.
2. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H and YM617 clinical study group. Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990;144:908-912.
3. Yamada S, Suzuki M, Tanaka C, Mori R, Kimura R, Inagaki O, Honda K, Asano M, Takenaka T, Kawabe K. Comparative study on α1-adrenoceptor antagonist binding in human prostate and aorta. Clin Pharmacol Physiol 1994;21:405-411.
4. Kawabe K, Moriyama N, Yamada S, Taniguchi N. Rationale for use of α-blockers in the treatment of benign prostatic hyperplasia (BPH). Int J Urol 1994;1:203-211.
5. Watanabe H, Kato H, Kato T, Morita M, Tanaka M, Terasawa Y. Diagnostic application of ultrasonography to the prostate. Jpn J Urol 1968;59:273-279.
6. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17: 477-486.
7. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-1577.
8. Aso Y, Homma Y. Clinical research criteria: response criteria for evaluating efficacy of treatments for benign prostatic hypertrophy. Br J Urol 1995;76(suppl 1):69-73.
9. Hanly JA, McNeil BJ. The meaning and use of area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
10. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461-475.
11. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980;68:745-756.
12. Kawabe K, Moriyama N, Hamada K, Ishima T. Density and localization of alpha 1-adrenoreceptors in hypertrophied prostate. J Urol 1990;143:592-595.
13. Tempany CMC, Partin AW, Zerhouni EA, Zinreich SJ, Walsh PC.The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 1993;22:39-42.
14. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995;45:258-265.
15. Harada M, Kinoshita Y, Moriyama M, Kondo I, Nakahashi M, Kumagai H, Sasaki K, Hosaka M. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 1994;25:147-155.
16. Shapiro E, Hartanto V, Lepor H.The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 192;21:297-307.
17. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
18. Abrahamsson P-A, Lija H, Falkmer S, Wadström LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.
19. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141:987-992.
20. Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994;44:199-205.
21. Benson MC, Whang IS, Olsson CA, McMahon DJ, Looner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-821.
22. Lepor H, Machi G. Comparison of the AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993;42: 36-40.
23. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 1994;44:153-155.